Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Convertible Debt: 2015-2024

Historic Convertible Debt for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Dec 2024 value amounting to $199.0 million.

  • Ironwood Pharmaceuticals' Convertible Debt rose 0.34% to $199.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $199.2 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $199.0 million for FY2024, which is 0.34% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Convertible Debt of $199.0 million as of FY2024, which was up 0.34% from $198.3 million recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Convertible Debt peaked at $430.3 million during FY2020, and registered a low of $198.3 million during FY2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Convertible Debt value was $199.0 million (recorded in 2024), while the average stood at $264.5 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Convertible Debt grew by 17.47% in 2022 and then slumped by 49.95% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Convertible Debt (Yearly) stood at $430.3 million in 2020, then declined by 21.60% to $337.3 million in 2021, then rose by 17.47% to $396.3 million in 2022, then plummeted by 49.95% to $198.3 million in 2023, then rose by 0.34% to $199.0 million in 2024.